Severe Insulin Lipodystrophy as a Possible Cause of Instability in Diabetics

Paley, Ronald G.; Scott, Mary

doi:10.1136/bmj.2.5108.1331

Cited by 12 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…But lipohypertrophy is not a recognized cause of variation in insulin absorption. 4 " 6 We have investigated the effect of lipohypertrophy at the injection site on insulin absorption in 12 diabetic individuals by comparing the clearance of 125 I-insulin injected simultaneously into two anatomically mirror image sites with and without lipohypertrophy.…”

mentioning

confidence: 99%

Diabetic Lipohypertrophy Delays Insulin Absorption

et al. 1984

View full text Add to dashboard Cite

The effect of lipohypertrophy at injection sites on insulin absorption has been studied in 12 insulin-dependent diabetic patients. The clearance of 125I-insulin from sites with lipohypertrophy was significantly slower than from complementary nonhypertrophied sites (% clearance in 3 h, 43.8 +/- 3.5 +/- SEM) control; 35.3 +/- 3.9 lipohypertrophy, P less than 0.05). The degree of the effect was variable but sufficient in several patients to be of clinical importance. Injection-site lipohypertrophy is another factor that modifies the absorption of subcutaneously injected insulin.

show abstract

mentioning

confidence: 99%

Diabetic Lipohypertrophy Delays Insulin Absorption

et al. 1984

View full text Add to dashboard Cite

show abstract

“…The first insulin treatments were relatively crude preparations of bovine or porcine pancreases. These were associated with lipodystrophy and allergic reactions [1][2][3] and, given their short-lived action, they were administered up to four times a day [4]. Once insulin could be crystallized, purer preparations were possible, and the formulation could be altered to lengthen the time-activity profile.…”

Section: The Evolving Saga Of Basal Insulin Developmentmentioning

confidence: 99%

Basal weekly insulins: the way of the future!

Rosenstock

Prato

2022

Metabolism

View full text Add to dashboard Cite

“…Pierwsze preparaty insulinowe otrzymywano z surowych trzustek bydlęcych i wieprzowych. Ich stosowanie wiązało się jednak z licznymi działaniami niepożądanymi 1,2 . Stopniowe postępy w diabetologii zaowocowały wynalezieniem długo działających analogów insuliny bazowej, które mogą być podawane raz dziennie 3 .…”

Section: Wprowadzenieunclassified

Icodec insulin - revolution in diabetes type 2 insulin therapy

Dobrzyński

Czarnota

Skubel

et al. 2022

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: Basal glucose control in diabetes type 2 is commonly maintained by a single, once-daily administration of insulin through subcutaneous injection. Insulin icodec, a novel ultralong-acting lipidated analog validates the concept of a once-weekly basal injection that is less burdensome, yet equally safe and efficacious as conventional once-daily treatment 1.Aim: The aim of the study is to introduce once-weekly injected insulin therapy and compare it with conventional basal insulin therapy in diabetes type 2 patients.Results: The results from phase II trials suggest that switching from an existing basal insulin to icodec, with or without a loading dose, provides effective glycemic control with comparable risk of hypoglycemia.In one of the studies TIR improved from baseline (mean: A 57.0%; B 55.2%; C 51.0%; IGlar U100 55.3%) through weeks 15 and 16 (estimated mean: A 76.6%; B 83.0%; C 80.9%; IGlar U100, 75.9%). No unexpected side effects were observed. It was reassuring that not a single episode of severe hypoglycemia (level 3) was reported for any treatment group throughout the trial duration and that the time spent below range (<3.9 mmol/L [<54 mg/dL]) during weeks 15 and 16 was well below the 4% target recommended by the International Consensus on Time in Range across all treatment groups 2.Conclusion: In conclusion,insulin icodec, a new acylated basal insulin analog, has been developed with optimized modifications to provide a long half-life suitable for weekly insulin dosing. In a patient population with type 2 diabetes receiving daily basal insulin therapy, switching to once-weekly icodec resulted in effective glycemic control without a transient elevation of fasting glucose levels during the switch and without increasing the risk of clinically relevant hypoglycemia compared with IGlar U100 2.Key words: Icodec, insulin, diabetes type 2

show abstract

Severe Insulin Lipodystrophy as a Possible Cause of Instability in Diabetics

Cited by 12 publications

References 5 publications

Diabetic Lipohypertrophy Delays Insulin Absorption

Diabetic Lipohypertrophy Delays Insulin Absorption

Basal weekly insulins: the way of the future!

Icodec insulin - revolution in diabetes type 2 insulin therapy

Contact Info

Product

Resources

About